A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Red Blood Cell Transfusion Dependence
Study Status
Open to Enrollment
Study Description
The purpose of this study is to see if people with primary myelofibrosis need fewer red blood cell transfusions after taking pomalidomide.
Celgene Corporation will work with the study doctor to find out the following information:
- What effect pomalidomide has on patients and their need for red blood cell transfusions
- What effect pomalidomide has on patient quality of life
- Whether there are changes in biomarkers in blood that could identify people who are likely to to respond or not respond to pomalidomide.
Biomarkers are substances in the blood, such as proteins and genetic material (also called RNA and DNA), that can be used to predict whether someone will respind to a treatment. These tests will NOT tell us if a disease is inherited. Note: these tests will not involve patients' family members.
Disease Status and/or Stage
Primary Myelofibrosis
Sponsor
Celgene Corporation
Key Eligibility
- Men and women age 18 and older
- Diagnosis of Myeloproliferative Neoplasm-associated Myelofibrosis
- Detailed eligibility discussed when you contact the study team
Principal Investigator
Contact
- Yulia Dault, RN
- (212) 746-4829
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
